

Code IMP
Company name Imexpharm Corporation
Date 10/27/2020
Subject Board resolution on business performance

Content:

Imexpharm Corporation announces the Board resolution dated October 26, 2020 as follows:

1. Approving the report on business performance in the first nine months of 2020:

No.	Item (VND billion)	Reality in 09 months of 2020	% Plan 2020	Compared to 09 months of 2019	Growth rate
1	Total revenue	893.4	51.1%	903.4	(1.1%)
2	Net revenue	882.4		886.4	(0.5%)
3	Profit before tax	167.3	64.3%	137.4	21.8%
4	Profit after tax	139.3		110.5	26.1%

2. Approving the report on the progress of Binh Duong High-Tech Plant (IMP4) and Testing Center.
3. Approving the report on business plan for Quarter 4 of 2020:

No.	Item (VND billion)	Quarter 4/2020	Year 2020	% Plan 2020	Year 2019	Growth rate
1	Total revenue	488.6	1.400.2	80.0%	1,420.7	(1.4%)
2	Profit before tax and before distributing to Science and Technology Fund	90.0	257.3	99.0%	222.4	15.7%
3	Profit before tax	90.0	257.3	99.0%	202.4	27.1%

4. Approving the proposal of the Board of Directors for handling bad debts with an amount of 2,147,571,703 dong.

5. Approving to authorize the CEO to decide a clearance price for the Company's property in Tan Phu District:
 - Address: 156/35 Phu Tho Hoa, Phu Tho Hoa ward, Tan Phu district, Ho Chi Minh city.
 - Area: 106 m2
 - Original price: 1,971,958,040 dongs
 - Clearance price: market price.
6. Approving to exercise the share purchase rights in Agimexpharm:
 - Outstanding volume: 12,835,177 shares
 - Issue ratio: 2.5:1
 - Offering volume: 5,134,070 shares
 - Offering value: 51,340,700,000 dongs
 - Issue price: 12,000 dongs/share
 - Total mobilized capital: 61,608,840,000 dongs
 - Estimated volume expected to be entitled to buy by Imexpharm: 1,693,928 shares

Of which:

 - Estimated buying volume: 437,184 shares
 - Estimated volume rejected to buy and transferred the share purchase rights at a price not lower than 6,000 dongs/right: 1,256,744 shares
 - Total estimated additional investment: 5,246,210,640 shares.